{"protocolSection":{"identificationModule":{"nctId":"NCT00350792","orgStudyIdInfo":{"id":"9941"},"secondaryIdInfos":[{"id":"H3E-FP-S099","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients","officialTitle":"A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients"},"statusModule":{"statusVerifiedDate":"2010-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-08"},"primaryCompletionDateStruct":{"date":"2008-11","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11","type":"ACTUAL"},"studyFirstSubmitDate":"2006-07-10","studyFirstSubmitQcDate":"2006-07-10","studyFirstPostDateStruct":{"date":"2006-07-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-11-05","resultsFirstSubmitQcDate":"2009-11-05","resultsFirstPostDateStruct":{"date":"2009-12-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-10-11","lastUpdatePostDateStruct":{"date":"2010-10-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer"},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":62,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Carboplatin","type":"EXPERIMENTAL","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles.","interventionNames":["Drug: pemetrexed","Drug: carboplatin"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles","armGroupLabels":["Pemetrexed + Carboplatin"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"carboplatin","description":"Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles","armGroupLabels":["Pemetrexed + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)","description":"Tumor response is defined as the percentage of patients with either a complete response or a partial response. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions and Partial Response=30% decrease in sum of longest diameter of target lesions.","timeFrame":"baseline to measured objective tumor response (up to six 21-day cycles)"}],"secondaryOutcomes":[{"measure":"Time to Treatment Failure","description":"Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.","timeFrame":"baseline to stopping treatment (up to six 21-day cycles)"},{"measure":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.","timeFrame":"baseline to date of death from any cause (up to 14.5 months)"},{"measure":"Estimated Probability of One Year Progression-free Survival","description":"Progression free survival (PFS) is the duration from enrollment until first disease progression or death. For patients not known to have died as of the data cut-off date and who do not have progressive disease, PFS is censored at the last radiological assessment date.","timeFrame":"baseline to measured progressive disease or death, 1 year"}],"otherOutcomes":[{"measure":"Time to Treatment Failure","description":"Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.","timeFrame":"baseline to stopping treatment (up to six 21-day cycles)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV\n* No previous chemotherapy for lung cancer\n* Men and women \\> or = 70 years\n* At least one uni-dimensionally measurable lesion (Response Evaluation Criteria In Solid Tumors \\[RECIST\\]criteria)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1\n\nExclusion Criteria:\n\n* Treatment within the last 30 days with a drug that has not received regulatory approval\n* Serious systemic disorders\n* Inability to discontinue administration of aspirin or anti-inflammatory non steroid\n* Concurrent administration of any other antitumor therapy\n* Brain metastasis","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bobigny","zip":"93009","country":"France","geoPoint":{"lat":48.90982,"lon":2.45012}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Le Mans","zip":"72000","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lille","zip":"59000","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nantes","zip":"44202","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vandœuvre-lès-Nancy","zip":"54511","country":"France","geoPoint":{"lat":48.66115,"lon":6.17114}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"62"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"33"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"}]},{"type":"Death from Study Disease","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Death from Study Drug Toxicity","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Death Not Study Drug Related","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"11"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"62"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76.5","spread":"3.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"11"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"51"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"62"}]}]}]},{"title":"Disease Stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]},{"title":"Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"49"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"52"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Large Cell Lung Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}]},{"title":"Adenocarcinoma of Lung","categories":[{"measurements":[{"groupId":"BG000","value":"32"}]}]},{"title":"Squamous Cell Carcinoma of Lung","categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}]},{"title":"Other: Carcinoma-Infiltrant Indifferencie","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Other: Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Other: Indifferencied Non-Small Cell Lung Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Other: Undifferentiated","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)","description":"Tumor response is defined as the percentage of patients with either a complete response or a partial response. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions and Partial Response=30% decrease in sum of longest diameter of target lesions.","populationDescription":"Patients qualified for tumor response analysis: treated patients, with measurable advanced non-small cell lung cancer (NSCLC) disease and at least one tumor assessment after the patient received at least a first cycle of chemotherapy (unless early progression occurs, including early clinical progressions confirmed by the assessment committee).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"baseline to measured objective tumor response (up to six 21-day cycles)","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"16.58","upperLimit":"43.26"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Treatment Failure","description":"Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.","populationDescription":"All treated patients. 29 patients were censored.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"weeks","timeFrame":"baseline to stopping treatment (up to six 21-day cycles)","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.95","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.","populationDescription":"All treated patients. 29 patients were censored.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"baseline to stopping treatment (up to six 21-day cycles)","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"10.1","upperLimit":"NA","comment":"Confidence interval is not calculable for the upper limit due to the immaturity of the data."}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.","populationDescription":"Twenty patients were censored as they were still alive at the time of the data cut-off.","reportingStatus":"POSTED","anticipatedPostingDate":"2010-11","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"baseline to date of death from any cause (up to 14.5 months)","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"9.1","upperLimit":"12.9"}]}]}]},{"type":"SECONDARY","title":"Estimated Probability of One Year Progression-free Survival","description":"Progression free survival (PFS) is the duration from enrollment until first disease progression or death. For patients not known to have died as of the data cut-off date and who do not have progressive disease, PFS is censored at the last radiological assessment date.","populationDescription":"Six patients were censored as they had not experienced a qualifying event (death or first disease progression) at the time of data cut-off.","reportingStatus":"POSTED","anticipatedPostingDate":"2010-11","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"baseline to measured progressive disease or death, 1 year","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"4.6","upperLimit":"21.6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 6 cycles.\n\nCarboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles.","seriousNumAffected":26,"seriousNumAtRisk":62,"otherNumAffected":61,"otherNumAtRisk":62}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":62}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":62}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":62}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":62}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":62}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":62}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Sigmoiditis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":62}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Catheter related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Tumour necrosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":62}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":62}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":35,"numAtRisk":62}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":12,"numAtRisk":62}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":115,"numAffected":44,"numAtRisk":62}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":29,"numAtRisk":62}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":62}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":62}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":21,"numAtRisk":62}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":62}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":14,"numAtRisk":62}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":42,"numAtRisk":62}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":62}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":62}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":6,"numAtRisk":62}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":23,"numAtRisk":62}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":62}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":62}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":25,"numAtRisk":62}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":62}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":62}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":62}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":62}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":62}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}